NASDAQ OMX

KLOX Technologies reports on final results from its clinical study on LumiHeal(TM) for the treatment of chronic wounds

3.5.2017 16:30 | NASDAQ OMX

Dela

LAVAL, Quebec, May 03, 2017 (GLOBE NEWSWIRE) -- Today, the final results on KLOX Technologies' (Klox) EUREKA study, which evaluated LumiHeal in the treatment of hard-to-heal, non-responsive, chronic wounds, were reported at the European Wound Management Association, in Amsterdam.

LumiHeal is a CE marked, first-in-class, proprietary, non-thermal and non-invasive treatment solution that utilizes hyper pulsed fluorescence light (HPFL) to treat acute and chronic wounds.

"LumiHeal has shown that it is a viable and effective treatment solution for patients with debilitating hard-to-heal, chronic wounds," stated Dr. Marco Romanelli, MD, PhD, Associate Professor of Dermatology at the School of Medicine, University of Pisa, and Chief of the Wound Healing Research Unit, and President Elect of the World Union of Wound Healing Societies. "LumiHeal represents a new option in the way practitioners can manage and treat hard-to-heal chronic wounds." 

"We are very pleased that the data released today confirmed the interim analysis reported in September 2016 on 33 patients," said Dr. Michel Cimon, MD, Senior Vice President, Chief Medical and Scientific Officer at Klox. "It's an important day for LumiHeal and for FB Advanced Wound Care, our wound care franchise."

Clinical final results from EUREKA study on LumiHeal(TM) and chronic wounds management

Professor Marco Romanelli reported the final study results on the evaluation of real-life use of LumiHeal in Chronic Wounds Management (Venus Leg Ulcers, Diabetic Foot Ulcers, and Pressure Ulcers). The results reported were on 99 patients who completed treatment in the EUREKA study.

Investigators' final analysis supports the strong efficacy profile of LumiHeal in promoting wound closure along with wound bed preparation in hard-to-heal chronic wounds. These results indicate LumiHeal's ability, in a majority of cases, to transition hard-to-heal, non-responsive, chronic wounds into an acute wound setting.   

Investigators found the treatment to be safe, easy to administer and very well tolerated by the subjects' population. Compliance to the study visits was excellent.

The excellent tolerability and compliance profiles is reinforced by the positive action on pain reduction observed during this study, especially in the VLU population.

Final results show:

Out of the 99 patients reported, 71% of them had a prognosis factor of poor healing at study entry;

The average treatment duration for all types of wounds was 80.5 days;

47 of these hard-to heal, chronic wounds, closed completely during the study period VLUs (26), DFUs (16), PU (5);

96% of wounds that closed completely, remained closed throughout the follow up period;

69.2% of VLUs and 68.8% of DFUs were ready for skin graft according to clinician's opinion;

The table below summarizes the top line data:

  Median
Wound Age
(Months)
Total Wounds
Treated
Total Wounds
Closed
Median
baseline area
(cm(2))
Median area
at last Study
visit
(cm(2))
p-value
VLU 9.3 52 32 6.85 0.40 <0.001
DFU 4.0 32 16 1.60 0.35 0.001
PU 12.5 15 5 1.90 1.20 0.268

The final results of the EUREKA study show, that taken together with efficacy, treatment ease of use, safety, and a positive impact on pain reduction, LumiHeal has the ability to become a leading option for the treatment and management of hard-to-heal, chronic wounds.

About LumiHeal(TM)
LumiHeal is a CE marked, first-in-class, proprietary, non-thermal and non-invasive treatment solution that generates hyper pulsed fluorescence light to treat acute and chronic wounds. It is used in conjunction with a multi-LED light. LumiHeal is a topical gel comprising of light absorbing molecules, which is applied to a wounded area. The HPFL generated have the capacity to penetrate various depths of the skin (epidermis, dermis, hypodermis). Treatment duration lasts only a number of minutes, while maintaining a safe and well tolerated product profile.

About KLOX Technologies
Klox is a specialty pharmaceutical company focused on developing and commercializing products based on its proprietary Fluorescence Biomodulation technology platform, previously known as BioPhotonics, to address skin and soft tissue disorders. Klox is advancing its programs as part of its multiple franchises focusing on indications across Dermatology, Wound Care, and Oral Health. For more information and to consult the abstracts, please visit www.kloxtechnologies.com.

Forward Looking Statements
Certain statements contained in this newswire, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward looking statements include those regarding cosmetics and medical devices and medical applications and clinical trials and the status and related results thereto, as well those regarding continuing and further development and commercialization efforts. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Klox Technologies Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the medical, cosmetics and/or consumer goods industries, changes in the regulatory environment in the jurisdictions in which Klox Technologies Inc. does business, financial and commercial markets volatility, fluctuations in costs, and changes to the competitive environment, as well as other risks. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing and further development efforts, specific risks which could cause actual results to differ materially from Klox Technologies Inc.'s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our products, final and quality controlled verification of data and the related analyses, and the expense and uncertainty of obtaining regulatory approval.

For more information:
Jade Lavallée Labossière
Hill+Knowlton Strategies
514-375-2730
Jade.lavallee-labossière@hkstrategies.ca




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: KLOX Technologies Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Gaining Momentum: Vricon Hires Barry Tilton as CTO and VP of Engineering21.7.2017 15:21Pressmeddelande

McLean, Virginia, July 20, 2017 (GLOBE NEWSWIRE) -- Vricon, a global leader in 3D imagery, is pleased to announce the addition of Barry Tilton, who will join Vricon Systems LLC as the Vice President of Engineering and CTO for U.S. Government Programs. Vricon's mission is to build The Globe in 3D by producing photorealistic 3D products and digital elevation models with unmatched coverage and delivery timelines. Tilton will spearhead efforts to create new content and improve response times and product quality for Vricon's customers. Tilton brings a unique and extensive background in the Defense and Intelligence communities, having worked in remote sensing systems design and user support for a range of customers, to include the Air Force Space program, the National Geospatial-Intelligence Agency, the National Reconnaissance Office, the Office of the Director of Intelligence, and the Under Secretary of Defense for Intelligence. Tilton also has experience in international technic

REG Celebrates Completion of Upgrade Project at Emden Biorefinery20.7.2017 19:46Pressmeddelande

EMDEN, Germany, July 20, 2017 (GLOBE NEWSWIRE) -- Renewable Energy Group, Inc. (NASDAQ:REGI) marked the completion of upgrades at its Emden, Germany biorefinery Wednesday with a ribbon cutting ceremony with government and community members. REG invested 2.5 million € for the installation of a new biodiesel distillation column and a thermal oil heater. &quot;This investment is another milestone in REG's European strategy to be a leader in delivering high quality biofuels,&quot; said Jean Scemama, Vice President, REG Energy Europe.  &quot;Within this strategy, Emden is positioned to perform well with deep water access to receive and deliver products by vessel and can now meet or exceed the highest quality standards required by our customers.&quot; &quot;This project is a result of teamwork across REG's teams in Europe and the U.S.&quot; said Brad Albin, Vice President, Manufacturing.  &quot;Upgrading Emden's distillation capability enables us to more effe

Constellation Brands Elects Susan Somersille Johnson of SunTrust Banks, Inc. to its Board of Directors20.7.2017 15:38Pressmeddelande

VICTOR, N.Y., July 20, 2017 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today that its board of directors increased the size of the board from 10 to 11 members. In addition, the board elected Susan Somersille Johnson, corporate executive vice president and chief marketing officer of SunTrust Banks, Inc., to serve as a member of the board, effective as of the close of business on July 18, 2017. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dfad4ec0-c876-49e9-9ff4-bc9f803b7cb1 &quot;We're pleased to welcome Susan to the board of directors,&quot; said Constellation's Chairman of the Board Richard Sands. &quot;Susan's deep understanding of brand strategy and marketing, as well as her passion for technology, will make a great addition to Constellation as we continue to build on the existing strengths of our board and the compan

Appian Extends its Capabilities with a New Robotic Digital Workforce Offering20.7.2017 15:00Pressmeddelande

Appian RPA with Blue Prism Brings Together Leading Business Process Management, Low-Code Application Development, and Robotic Process Automation (RPA) RESTON, Va., July 20, 2017 (GLOBE NEWSWIRE) -- Appian, (NASDAQ:APPN), a leading global provider of low-code application development and BPM software, today announced the addition of Blue Prism's industry leading Robotic Process Automation (RPA) capabilities to its platform. The new product offering, Appian RPA with Blue Prism, brings together leading low-code application development, BPM, and robotic workforce software for the first time as an offering from a single vendor. This offering builds on an already well-established partnership while giving organizations a one-stop-shop for all their enterprise automation needs, especially those that require the highest levels of auditing, security and scalability. &quot;Appian's platform is now extended with robotic process automation from Blue Prism,&quot; said Matt

Jennifer Powers to join Global Infrastructure Partners as a Partner and Chair of GIP's Credit Business19.7.2017 18:16Pressmeddelande

For Immediate Release New York, July 19, 2017 (GLOBE NEWSWIRE) -- Global Infrastructure Partners (GIP), the leading, independent global infrastructure investment firm, announced today that Jennifer Powers will join GIP in September as a Partner and Chair of GIP's Credit Business. Ms. Powers will work closely with GIP Partner Jon Bram and GIP CAPS Fund Managing Partners Reiner Boehning and Steve Cheng to build out and expand GIP's Credit Business into a market leader in providing financing for infrastructure assets and projects. Ms. Powers joins GIP from Mizuho Bank where she was co-head of Investment Grade Debt Capital Markets. Prior to Mizuho, she was a founding member of the Royal Bank of Scotland's Credit Markets Business. Ms. Powers also spent 12 years in the energy investment banking and capital markets departments of Credit Suisse. Ms. Powers has extensive experience in advising and financing clients in the energy and infr

Solar Street Lights Illuminate Bujumbura, Burundi19.7.2017 16:10Pressmeddelande

Solar Pioneer Gigawatt Global Expands its Green Energy Offerings in Africa &quot;By expanding our investments from commercial scale projects to include off-grid additionally, we are positively impacting the lives of millions of people in Burundi and throughout Africa&quot; -  Yosef I. Abramowitz, CEO, Gigawatt Global  BUJUMBURA, Burundi, July 19, 2017 (GLOBE NEWSWIRE) -- Downtown Bujumbura just got a little brighter, thanks to an innovative partnership between Mayor Freddy MBONIMPA and Gigawatt Global (http://GigawattGlobal.com), a founding member of United States Power Africa's Beyond the Grid program. [Access multimedia content here:  http://APO.af/ePScuQ/ http://APO.af/xxruhc/  http://APO.af/gdfypU/ http://APO.af/Xpw3uh ] This week solar-powered 'light islands' began appearing in the heavily-trafficked central bus station and

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum